| abstract |
The present invention relates to compounds of formula I (wherein R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkylamino, di- (lower alkyl) - R2 is optionally substituted phenyl, lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, lower alkylamino, or di (lower alkyl) amino; 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, naphthalen-2-yl, indan-5-yl, lower alkenylphenyl, 5,6,7,8-tetrahydro naphthalenyl, 2,3-dihydroisoindol-2-yl, 1,2,3,4-tetrahydronaphthalenyl, benzofuran-2-yl, benzo [b] thiophen-2-yl, lower alkyl phenyl, 3,4-dihydro-1H-isoquinolin-2-yl or thiophen-3-yl; R3 and R4 are independently hydrogen or lower alkyl: R5 is hydrogen, lower alkyl; lower alkyl, -CH 2 OH, or -CH 2 NR 6 R 7: R 6 and R 7 are each independently hydrogen, lower alkyl, - (CH 2) n -phenyl, cycloalkyl, - (CH 2) m -morpholinyl; or R6 and R7 together with the nitrogen atom form a saturated ring containing from 4 to 6 carbon atoms; n is 0-3: m is 2 or 3: X is -NR8 - or -O-; or X and R 5 together form N (CH 2) 2: or X and R 3 together form N (CH 2) 3; and R8 are hydrogen or lower alkyl) and their pharmaceutically acceptable acid addition salts, with the exception of (6-chloro-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol: (6-methyl-2- phenyl-4-quinolinyl) - (+) - 2-aminobutanol; (6-methoxy-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol; and (8-methoxy-2-phenyl-4-quinolinyl) - (+) - 2-aminobutanol. The compounds of the present invention are useful in the treatment of disorders associated with NMDA receptor specific blockers. SHE |